Kolon TissueGene, Inc. (KOSDAQ:950160)
11,740
-400 (-3.29%)
Nov 20, 2026, 3:30 PM KST
Kolon TissueGene Revenue
Kolon TissueGene had revenue of 819.27M KRW in the quarter ending June 30, 2026, a decrease of -39.02%. This brings the company's total for the last twelve months to 4.80B, down -12.58% year-over-year. In the year 2025, Kolon TissueGene had annual revenue of 5.16B with 1.68% growth. That makes Kolon TissueGene the 41,046th largest company in the world by revenue and 2,528th in South Korea.
Revenue (ttm)
4.80B
Revenue Growth
-12.58%
P/S Ratio
207.97
Revenue / Employee
165.40M
Employees
29
Market Cap
997.55B
Revenue by Segment
- Bio 7.55B 79.9%
- Complex Distribution 1.91B 20.1%
Fiscal year ended Dec 31, 2022 See the full Kolon TissueGene breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.16B | 85.27M | 1.68% |
| Dec 31, 2024 | 5.07B | 1.37B | 36.90% |
| Dec 31, 2023 | 3.71B | -5.75B | -60.81% |
| Dec 31, 2022 | 9.46B | 5.45B | 136.22% |
| Dec 31, 2021 | 4.00B | 447.31M | 12.58% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chabiotech | 1.31T |
| LigaChem Biosciences | 71.90B |
| Komipharm International | 53.02B |
| ABL Bio | 34.28B |
| Pharmicell | 23.94B |
| OliX Pharmaceuticals | 13.64B |
| Peptron | 6.00B |
| Voronoi | 4.16B |
Kolon TissueGene News
- 9 days ago - Kolon TissueGene Quarterly report: Q3 2026 - Filings
- 3 months ago - Kolon TissueGene Quarterly report: Q2 2026 - Filings
- 6 months ago - Kolon TissueGene Quarterly report: Q1 2026 - Filings
- 8 months ago - Kolon TissueGene Annual report: Q4 2025 - Filings